Comparative Pharmacology
Head-to-head clinical analysis: NUROMAX versus PANCURONIUM BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUROMAX versus PANCURONIUM BROMIDE.
NUROMAX vs PANCURONIUM BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neuromuscular blocking agent; competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing depolarization and muscle contraction.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and thus inhibiting muscle contraction.
0.1 mg/kg IV bolus, then 0.015 mg/kg IV as needed for neuromuscular blockade.
0.04-0.1 mg/kg IV initial bolus, then 0.01-0.02 mg/kg IV every 20-40 min as needed for neuromuscular blockade.
None Documented
None Documented
Terminal half-life: 1.5-2.5 hours; prolonged in renal impairment (up to 5 hours) and hepatic disease
Terminal elimination half-life: 100-120 minutes in adults with normal renal function; prolonged to 240-480 minutes in renal failure.
Renal: 80-90% unchanged; biliary: 10-20%
Renal: 50-70% unchanged; biliary/fecal: 5-10% as metabolites; minor hepatic metabolism.
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent